UK Biobank is one of the largest biomedical databases in the world, containing health, genetic and lifestyle data from over 500,000 participants in the United Kingdom. It has become a foundational resource for studying disease, and it is changing how early-stage drug discovery is approached.
What the database holds
Participants were recruited between 2006 and 2010 and agreed to share their biological samples and health records over time. The dataset includes blood, urine, imaging data and detailed medical histories, which allows researchers to study how diseases develop over decades. Today, UK Biobank provides access to researchers worldwide, who use it to study conditions such as cancer, heart disease and neurological disorders.
The range of data types is wide. It runs from sociodemographics, lifestyle factors, mental health and cognitive tests to brain and heart MRI, carotid ultrasound and whole-body DXA scans of bones and joints. There are measures of blood pressure, arterial stiffness, heart and lung function, physical activity, and body size and composition. Urine and blood samples provide genetics, proteins, biochemical measures and low-molecular-weight metabolites. All of it is linked to primary and secondary care records and to death and cancer registers.
Connecting genes to health outcomes
UK Biobank allows researchers to connect genetic data with real health outcomes at scale. That makes it possible to identify links between genes, lifestyle and disease risk.
The database contains thousands of variables per participant, including imaging, genomic sequencing and biomarker data. This depth lets researchers run large-scale studies that would not be possible in smaller datasets. UK Biobank has supported over 18,000 peer-reviewed studies and is widely used in research on cancer, cardiovascular disease and aging.
A new starting point for drug discovery
Drug development moves through five phases: discovery and development, preclinical research, clinical research, FDA review and FDA post-market safety monitoring. UK Biobank is changing the earliest of these. Instead of relying on small clinical samples, researchers can now identify disease patterns using large population-level data.
The database includes over 15 million biological samples and tens of petabytes of data, making it one of the most comprehensive resources for biomedical research. That scale improves the ability to identify drug targets with higher confidence.
By improving target selection, large datasets like UK Biobank can help reduce failure rates in clinical trials. This is critical in an industry where drug development can take over a decade and requires significant capital investment.
Data as a core asset
UK Biobank shows how biological data is becoming a core asset in biotechnology. The value is no longer just in physical samples, but in the ability to generate insights from large datasets.
At the same time, this model raises important questions around data access and control. Over 30,000 researchers across more than 90 countries now use UK Biobank data, which highlights its global influence.
Looking forward, the competitive edge in biotech may depend on who can best use large-scale biological data. Platforms like UK Biobank are shaping how future discoveries are made.